SOURCE: Glycology, Inc.

October 11, 2005 10:56 ET

Donna Murdoch, Experienced Marketing and Investment Executive, Named President of Glycology, Inc.

PHILADELPHIA, PA -- (MARKET WIRE) -- October 11, 2005 -- Donna Murdoch, has been named President of Glycology, Inc. (OTC: GYLG) (www.glycology.com), the producer of Celsync™ (www.celsync.com) the first all-natural nutrient, based on recent Noble Prize winning research (1994, 1999, 2000 and 2001) that identified cell-to-cell communications as the key to slow the aging process, improve performance and inhibit disease.

Ms. Murdoch, who will be responsible for Glycology's overall operations, brings a wide range of business development, marketing and investment expertise to the company. Prior to joining Glycology, she was Director of Business Development, for Raven Investments, LLP. She served as VP of Marketing for AT&T Mail (the first commercial email system) and as VP of Marketing for The Source, a joint venture between Knight Ridder and H&R Block (the first commercial online service).

Throughout her career Ms. Murdoch has demonstrated a keen understanding and ability to capitalize on emerging science and technology. She has been a consultant, advisor and venture investor for many companies that include: Kurant Corporation (recently acquired by eBay), Patchlink Corporation, Offroad Capital Markets and Five Below.

Ms. Murdoch is a graduate of The Baldwin School in Bryn Mawr, PA and earned her Bachelor of Business Administration from the University of Pennsylvania's Wharton School.

About Glycology, Inc.

Glycology, Inc. (www.glycology.com) is a lifesciences company focused on the discovery, development and marketing of neutraceutical preparations and supplements that enhance health, and wellbeing, as well as prevent and treat a broad range of illnesses. Its flagship product Celsync™ (www.celsync.com) is a breakthrough dietary supplement based on Nobel Prize winning research. It is capitalizing on an entire new science, called Glycobiology just now emerging at universities and medical centers to study saccharides that surround cells to prevent cellular transfer abnormalities and defend against disease. Saccharides are proving to be the agents necessary for the correct function of the immune system by enabling cells to create their own defenses. Glycology, Inc. is the first company to capitalize on these amazing scientific breakthroughs by commercializing Celsync™.

Forward-Looking Statements:

With the exception of historical information, this news release and accompanying information may include forward-looking statements that involve a number of risks and uncertainties. Actual results could differ materially from those anticipated as a result of various risks. There are numerous factors that could contribute to such differences, therefore such projected events and anticipated results are not warranties or guaranties that such events will occur or that the Company will achieve such results. For more information about this corporation and risks involved in the investment of their publicly traded shares, please see the company's website(s), and/or documents filed with the SEC, which are easily accessible in the EDGAR database system.

Contact Information